ADC Drugs Already Marketed Globally: Compilation of Technical Reviews

ADC (Antibody Drug Conjugate) is a complex that connects cytotoxic drugs to monoclonal antibodies targeting tumors, combining the characteristics of targeted drugs and chemotherapy drugs to achieve precise treatment. The concept of ADC drugs was proposed as early as 1900, but due to technical limitations, it remained theoretical for a long time. Between 1990 and 2000, monoclonal antibody drugs gained widespread clinical application, reducing the barriers to developing ADC drugs.

If you want to buy ADC Drug related products, here are some ADC linkers provided by AxisPharm:

Cleavable Linkers for Antibody-Drug Conjugates

Diketone PEG – ADC Linkers

β-Glucuronide Linkers

Disulfide Linkers

Branched PEG NHS ester – ADC Linkers

Target Specific Linkers

Figure 1 ADC Drugs Technology Development

There are two main pathways through which ADCs exert their antitumor activity: first, the specific mAb binds to the targeted cell surface antigen, is internalized by the tumor cell, processed by the endolysosomal system, and the payload (Payloads and Linker modified Payloads) is released into the cytoplasm, ultimately inducing apoptosis through cytotoxic pathways; second, tumor cell death is induced through the bystander killing effect.

Read more about ADC linker related articles:

What is ADC(Antibody-drug Conjugates)?

What is the difference between ADC linker and PEG linker?

ADC Linker Design and ADC Empowerment

Advances in ADC Linker Research

ADC to XDC, Five Major Elements of Antibody Conjugate Drugs, Exploring the Fundamental Source of Innovation

By the end of 2022, 15 ADC drugs had been approved globally, including Pfizer’s Mylotarg and Besponsa, Roche’s Kadcyla and Polivy, AstraZeneca’s Lumoxiti and Enhertu, Seagen/Takeda’s Adcetris, Seagen/Astellas’ Padcev, Seagen/Genmab’s Tivdak, GlaxoSmithKline’s Blenrep, Gilead’s Trodelvy, Rakuten Medical’s Akalux, ADC Therapeutics’ Zynlonta, RemeGen’s Aidixi, and ImmunoGen/Huadong Medicine’s Elahere, which was approved on November 15, 2022. These drugs treat diseases such as lymphoma, leukemia, breast cancer, multiple myeloma, head and neck cancer, and urothelial carcinoma. It is expected that by 2030, the ADC market will exceed $15 billion. ADCs combine cytotoxic molecules or drugs with tumor-targeting monoclonal antibodies through linkers, featuring the characteristics of both targeted drugs and chemotherapy drugs, enabling precise treatment and offering the dual advantages of small molecule drugs and antibody drugs.

Table 1 Globally Approved ADC Drugs

Explore more about Services provided by AxisPharm:

Formulation Services

Bioconjugation Service

Analytical Services

ICP-MS Service

Proteomics Services

Bioanalytical Service – PK Studies